Chemomab Therapeutics to Participate in H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotechnology company, will participate in the virtual H.C. Wainwright Global Investment Conference from May 23-26, 2022. Management will deliver a corporate overview webcast available on demand starting at 7:00 am ET on May 24. Additionally, Chemomab will engage in one-on-one meetings with investors. The company focuses on innovative therapeutics for fibrotic and inflammatory diseases, with its CM-101 monoclonal antibody currently in Phase 2 trials for severe conditions like primary sclerosing cholangitis and lung fibrosis.

TEL AVIV, Israel, May 18, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that management will participate in the virtual portion of the H.C. Wainwright Global Investment Conference, which will take place May 23-26, 2022.

HC Wainwright Global Investment Conference

Date:                Webcast available on demand starting at 7:00am ET May 24 – May 26, 2022

Format:            Corporate overview webcast

Webcast Link:  https://journey.ct.events/view/47c6f14e-2e3e-4baf-9592-cf2d6c3317f5

Replay:             Available at Chemomab website at investors.chemomab.com/events 

Chemomab is also participating in one-on-one meetings with investors. For more information, visit hcwevents.com/globalconference/.

About Chemomab Therapeutics Ltd.
Chemomab is a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is currently in Phase 2 trials for primary sclerosing cholangitis and liver fibrosis, with a Phase 2 trial in systemic sclerosis expected to begin in late 2022.

Contacts:
Investor Relations:	Media:
Irina Koffler	Barbara Lindheim
LifeSci Advisors, LLC	Chemomab Therapeutics
Phone: +1 917-734-7387	Consulting Vice President
ir@chemomab.com	Investor & Public Relations,
	Strategic Communications
	Phone: +1 917-355-9234
	barbara@chemomab.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-participate-in-hc-wainwright-global-investment-conference-301549851.html

SOURCE Chemomab Therapeutics, Ltd.

FAQ

What is Chemomab Therapeutics's participation in the H.C. Wainwright Global Investment Conference 2022?

Chemomab Therapeutics will participate in the H.C. Wainwright Global Investment Conference from May 23-26, 2022, providing a corporate overview webcast.

When will the Chemomab Therapeutics conference webcast be available?

The conference webcast for Chemomab will be available on demand starting at 7:00 am ET on May 24, 2022.

What is the focus of Chemomab Therapeutics?

Chemomab Therapeutics focuses on developing innovative therapeutics for fibrotic and inflammatory diseases with high unmet needs.

What is CM-101 and its significance for Chemomab Therapeutics?

CM-101 is a monoclonal antibody developed by Chemomab that targets the soluble protein CCL24, showing potential to treat severe fibrotic and inflammatory diseases.

What are the ongoing trials for Chemomab's CM-101?

CM-101 is currently in Phase 2 trials for primary sclerosing cholangitis and liver fibrosis, with a trial for systemic sclerosis expected to start in late 2022.